Company
Newsroom.
Our press releases provide you with detailed information about Ottobock's products, social responsibility and global presence. Learn about the latest technologies and current highlights in the medical technology sector. As a company that conducts research, we feature numerous interesting topics.
Press releases.
Friday, 2 October 2026
Skilled trades becoming a growth market for exoskeletons.
‘SUITX by Ottobock’ expands sales reach and partnerships across Europe.
‘SUITX by Ottobock’ expands sales reach and partnerships across Europe.
Tuesday, 22 September 2026
Two Turning Points, One Extraordinary Story: Ottobock Launches Documentary About Paralympic Swimmer Andreas Onea.
An extraordinary life story, innovative technology and a live event in Berlin: Ottobock celebrates the launch of the documentary “TWO. The Andreas Onea Story” with a film premiere and a live podcast recording.
An extraordinary life story, innovative technology and a live event in Berlin: Ottobock celebrates the launch of the documentary “TWO. The Andreas Onea Story” with a film premiere and a live podcast recording.
Tuesday, 2 September 2026
“I Am 80 Percent Human and 20 Percent Technology.”
Sarah de Lagarde hosts the new season of Taste of Bionics, Ottobock’s podcast.
Sarah de Lagarde hosts the new season of Taste of Bionics, Ottobock’s podcast.
Monday, 31 August 2026
Running, Learning, Exploring: Ottobock Running Clinics.
People with limb loss gain new confidence in their abilities through sport.
People with limb loss gain new confidence in their abilities through sport.
Thursday, 13 August 2026
Ottobock strongly increases revenue in the first half of the year and significantly improves its margin.
• Core revenues increase by 7.7 percent to EUR 818.5 million with organic core revenue growth of 6.7 percent
• Underlying core EBITDA grows by 18.1 percent to EUR 207.0 million; core EBITDA margin reaches 25.3 percent
• Strategic investment in future human-machine interface technology through Blue Arbor Technologies, Inc.
• Expansion of product portfolio in the field of Functional Electrical Stimulation through acquisition of Fesia Technology
• Expansion of global Patient Care network in Norway
• Portfolio streamlining continued: Sale of the "human mobility" wheelchair business agreed
• Full-year 2026 guidance narrowed: Organic core revenue growth of 6–8 percent (previously: 5–8 percent) and underlying core EBITDA margin of > 27 percent (previously > 26.5 percent)
• Core revenues increase by 7.7 percent to EUR 818.5 million with organic core revenue growth of 6.7 percent
• Underlying core EBITDA grows by 18.1 percent to EUR 207.0 million; core EBITDA margin reaches 25.3 percent
• Strategic investment in future human-machine interface technology through Blue Arbor Technologies, Inc.
• Expansion of product portfolio in the field of Functional Electrical Stimulation through acquisition of Fesia Technology
• Expansion of global Patient Care network in Norway
• Portfolio streamlining continued: Sale of the "human mobility" wheelchair business agreed
• Full-year 2026 guidance narrowed: Organic core revenue growth of 6–8 percent (previously: 5–8 percent) and underlying core EBITDA margin of > 27 percent (previously > 26.5 percent)
5 results out of 327